Keith  Crandell net worth and biography

Keith Crandell Biography and Net Worth

Director of Twist Bioscience
Keith L. Crandell serves as Independent Director of the Company. Mr. Crandell has served as a managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies. He serves on the board of directors of Twist Bioscience Corporation, a publicly traded synthetic biology company. From 2007 to 2019, he served on the board of directors of Adesto Technologies Corporation, a publicly traded provider of application specific and ultra-low power non-volatile memory products. He is also a director of several private companies and he also serves as a director of the Illinois Venture Capital Association. Mr. Crandell has a B.S. degree in chemistry and mathematics from St. Lawrence University, an M.S. degree in chemistry from the University of Texas at Arlington and an M.B.A. from the University of Chicago. Mr. Crandell's qualifications for service as a member of our board of directors include his financial expertise and his substantial experience as an investor in emerging companies.

What is Keith Crandell's net worth?

The estimated net worth of Keith Crandell is at least $20,523.78 as of August 12th, 2021. Mr. Crandell owns 486 shares of Twist Bioscience stock worth more than $20,524 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Crandell may own. Learn More about Keith Crandell's net worth.

How do I contact Keith Crandell?

The corporate mailing address for Mr. Crandell and other Twist Bioscience executives is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. Twist Bioscience can also be reached via phone at (800) 719-0671 and via email at [email protected]. Learn More on Keith Crandell's contact information.

Has Keith Crandell been buying or selling shares of Twist Bioscience?

Keith Crandell has not been actively trading shares of Twist Bioscience in the last ninety days. Most recently, Keith Crandell sold 1,412 shares of the business's stock in a transaction on Thursday, August 12th. The shares were sold at an average price of $106.93, for a transaction totalling $150,985.16. Following the completion of the sale, the director now directly owns 486 shares of the company's stock, valued at $51,967.98. Learn More on Keith Crandell's trading history.

Who are Twist Bioscience's active insiders?

Twist Bioscience's insider roster includes William Banyai (Insider), Robert Chess (Director), Keith Crandell (Director), Mark Daniels (Insider), Patrick Finn (Insider), Paula Green (SVP), Jan Johannessen (Director), Emily Leproust (CEO), James Thorburn (CFO), and Patrick Weiss (COO). Learn More on Twist Bioscience's active insiders.

Are insiders buying or selling shares of Twist Bioscience?

In the last year, insiders at the sold shares 63 times. They sold a total of 140,970 shares worth more than $6,128,183.34. The most recent insider tranaction occured on November, 11th when insider Dennis Cho sold 1,507 shares worth more than $72,336.00. Insiders at Twist Bioscience own 3.9% of the company. Learn More about insider trades at Twist Bioscience.

Information on this page was last updated on 11/11/2024.

Keith Crandell Insider Trading History at Twist Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2021Sell1,412$106.93$150,985.16486View SEC Filing Icon  
12/7/2020Sell75,000$103.40$7,755,000.001,412View SEC Filing Icon  
11/2/2018Buy75,000$14.00$1,050,000.00View SEC Filing Icon  
See Full Table

Keith Crandell Buying and Selling Activity at Twist Bioscience

This chart shows Keith Crandell's buying and selling at Twist Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Twist Bioscience Company Overview

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $42.23
Low: $40.87
High: $42.96

50 Day Range

MA: $43.88
Low: $36.89
High: $47.99

2 Week Range

Now: $42.23
Low: $23.07
High: $60.90

Volume

716,370 shs

Average Volume

901,886 shs

Market Capitalization

$2.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78